CLLS PE Ratio & Valuation,Is CLLS Overvalued

CLLS Relative Valuation

CLLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLLS is overvalued; if below, it's undervalued.

Historical Valuation

Cellectis SA (CLLS) is now in the Fair zone, suggesting that its current forward PS ratio of 4.81 is considered Fairly compared with the five-year average of -1.91. The fair price of Cellectis SA (CLLS) is between 3.11 to 8.17 according to relative valuation methord.

Relative Value

Fair Zone

3.11-8.17

Current Price：4.55

Fair

-4.69

-4.43

EV/EBITDA

Cellectis SA. (CLLS) has a current EV/EBITDA of -4.43. The 5-year average EV/EBITDA is -2.70. The thresholds are as follows: Strongly Undervalued below -6.59, Undervalued between -6.59 and -4.64, Fairly Valued between -0.76 and -4.64, Overvalued between -0.76 and 1.19, and Strongly Overvalued above 1.19. The current Forward EV/EBITDA of -4.43 falls within the Historic Trend Line -Fairly Valued range.

-5.35

EV/EBIT

Cellectis SA. (CLLS) has a current EV/EBIT of -5.35. The 5-year average EV/EBIT is -2.33. The thresholds are as follows: Strongly Undervalued below -5.60, Undervalued between -5.60 and -3.97, Fairly Valued between -0.70 and -3.97, Overvalued between -0.70 and 0.94, and Strongly Overvalued above 0.94. The current Forward EV/EBIT of -5.35 falls within the Undervalued range.

4.81

Cellectis SA. (CLLS) has a current PS of 4.81. The 5-year average PS is 5.36. The thresholds are as follows: Strongly Undervalued below -1.28, Undervalued between -1.28 and 2.04, Fairly Valued between 8.68 and 2.04, Overvalued between 8.68 and 12.00, and Strongly Overvalued above 12.00. The current Forward PS of 4.81 falls within the Historic Trend Line -Fairly Valued range.

-2.75

P/OCF

Cellectis SA. (CLLS) has a current P/OCF of -2.75. The 5-year average P/OCF is -1.80. The thresholds are as follows: Strongly Undervalued below -7.04, Undervalued between -7.04 and -4.42, Fairly Valued between 0.82 and -4.42, Overvalued between 0.82 and 3.44, and Strongly Overvalued above 3.44. The current Forward P/OCF of -2.75 falls within the Historic Trend Line -Fairly Valued range.

-4.13

P/FCF

Cellectis SA. (CLLS) has a current P/FCF of -4.13. The 5-year average P/FCF is -60.67. The thresholds are as follows: Strongly Undervalued below -566.37, Undervalued between -566.37 and -313.52, Fairly Valued between 192.18 and -313.52, Overvalued between 192.18 and 445.03, and Strongly Overvalued above 445.03. The current Forward P/FCF of -4.13 falls within the Historic Trend Line -Fairly Valued range.

Cellectis SA (CLLS) has a current Price-to-Book (P/B) ratio of 3.46. Compared to its 3-year average P/B ratio of 1.58 , the current P/B ratio is approximately 118.30% higher. Relative to its 5-year average P/B ratio of 1.65, the current P/B ratio is about 108.78% higher. Cellectis SA (CLLS) has a Forward Free Cash Flow (FCF) yield of approximately -8.82%. Compared to its 3-year average FCF yield of -17.11%, the current FCF yield is approximately -48.41% lower. Relative to its 5-year average FCF yield of -31.10% , the current FCF yield is about -71.62% lower.

3.46

P/B

Median3y

1.58

Median5y

1.65

-8.82

FCF Yield

Median3y

-17.11

Median5y

-31.10

Competitors Valuation Multiple

The average P/S ratio for CLLS's competitors is 7.24, providing a benchmark for relative valuation. Cellectis SA Corp (CLLS) exhibits a P/S ratio of 4.81, which is -33.54% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CLLS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CLLS in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Cellectis SA (CLLS) currently overvalued or undervalued?

What is Cellectis SA (CLLS) fair value?

CLLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cellectis SA (CLLS) is between 3.11 to 8.17 according to relative valuation methord.

How does CLLS's valuation metrics compare to the industry average?

What is the current P/B ratio for Cellectis SA (CLLS) as of Jan 08 2026?

As of Jan 08 2026, Cellectis SA (CLLS) has a P/B ratio of 3.46. This indicates that the market values CLLS at 3.46 times its book value.

What is the current FCF Yield for Cellectis SA (CLLS) as of Jan 08 2026?

As of Jan 08 2026, Cellectis SA (CLLS) has a FCF Yield of -8.82%. This means that for every dollar of Cellectis SA’s market capitalization, the company generates -8.82 cents in free cash flow.

What is the current Forward P/E ratio for Cellectis SA (CLLS) as of Jan 08 2026?

As of Jan 08 2026, Cellectis SA (CLLS) has a Forward P/E ratio of -4.69. This means the market is willing to pay $-4.69 for every dollar of Cellectis SA’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cellectis SA (CLLS) as of Jan 08 2026?

As of Jan 08 2026, Cellectis SA (CLLS) has a Forward P/S ratio of 4.81. This means the market is valuing CLLS at $4.81 for every dollar of expected revenue over the next 12 months.

CLLS Valuation